APOE and Alzheimer disease: Recently, clinical trials showed that monoclonal antibodies directed against Aβ slows disease progression in AD.3, 4, 5 However, some subgroups, most notably APOE4 carriers, exhibit lower treatment response and higher frequency of amyloid-related imaging abnormalities (ARIA).6